Drug Profile
Research programme: diabetes therapy - Metabolic Pharmaceuticals
Alternative Names: ADD 9918/ADD 9922; Diabetes therapy research programme - Metabolic PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Metabolic Pharmaceuticals
- Developer Calzada
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Australia
- 03 Mar 2004 Preclinical trials in Type-2 diabetes mellitus in Australia (unspecified route)